AI operations for regulated life sciences | Call us: +1 888-835-1270 | labs@rxqmsr.com
Insights

AI compliance intelligence
for life sciences.

FDA alerts, regulatory shifts, and AI adoption strategies — written by practitioners who know the difference between a 483 observation and an MCP server.

Breaking Intelligence — April 2026
FDA Warning Letter
FDA Just Put Life Sciences AI on Notice.
Here's What Every QA Director Needs to Know.
In April 2026, the FDA issued a Warning Letter citing a pharmaceutical manufacturer for improper use of AI in regulated manufacturing operations — the first of its kind to expand scrutiny beyond whether an AI system is a device to how AI is used in compliance-sensitive workflows. The message is unambiguous: you are fully responsible for every AI-generated output in your facility.
April 2026 · 8 min read · Read the brief →
Market Signal
Anthropic and Goldman Just Spent $1.5B Validating RxQMSR's Thesis
The big AI ventures are coming for your market. They'll learn 21 CFR on your time. Here's what it means and how to get ahead of it.
May 2026·5 min →
Medical Device
QMSR 2026 Is a Forcing Function. Make It an AI Opportunity.
The FDA's QMSR update aligns U.S. oversight with ISO 13485:2016. Your QMS is changing anyway — here's how to embed AI agents into the refresh.
April 2026·6 min →
Strategy
95% of AI Pilots Fail in Regulated Environments. Here's Why.
Generic, horizontal AI tools don't survive contact with 21 CFR. Vertical, compliance-aware agents do. The difference isn't the model — it's the design.
March 2026·7 min →